CareHub Clinical Trials Search

The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary g...

Ages: 18 Years up to 75 Years (ALL) — * Men and women of all races and ethnicities • * Age 18-75 years • * Documented diagnosis of chronic or episodic migraine for at least 6 months, based on International Classification of Headache Disorders, 3rd edition...

American University (Washington D.C., District of Columbia)

Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo...

Ages: 25 Years up to 85 Years (ALL) — 1. Patients with active or frequent Meniere's Disease. • 2. Male or female between the ages of 25 to 85 years. • 3. Subject must be compliant with the medication and attend study visits.

University of California, Irvine Medical Center ENT Clinic (Pavilion 2) (Orange, California)

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.

Ages: 18 Years up to 99 Years (FEMALE) — * Age 18 years or older (at time of signing the informed consent) • * Currently pregnant • * The outcome of the pregnancy must not be known

IQVIA Virtual Site (Durham, North Carolina)

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezu...

Ages: 18 Years (ALL) — * Migraine diagnosis according to ICHD-III. • * Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to loca...

University of Miami, Miller School of Medicine (Miami, Florida)

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participan...

Ages: 18 Years (ALL) — * Meets International Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura • * At least 18 years of age • * 2- 8 migraine attacks per month

Mayo Clinic in Arizona (Phoenix, Arizona)

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

Ages: 6 Years up to 17 Years (ALL) — 1. History of migraine (with or without aura) for ≥ 6 months before Screening. • 2. History of 1 to 8 moderate or severe attacks per month during the 2 months prior to screening. • 3. 1 or more migraine days requiring...

Advanced Research Center, Inc. (Anaheim, California); ProScience Research Group (Culver City, California); Neuro-Pain Research Center (Fresno, California)

The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a sing...

Ages: 18 Years (ALL) — * First Degree Relatives of Patients with MS, or • * Patients who have received anti-TNFa therapy as treatment for inflammatory diseases other than MS such as Crohn's disease, psoriasis and rheumatoid arthritis, or • ...

National Institute of Neurological Disorders and Stroke (Bethesda, Maryland); Massachusetts General Hospital (Boston, Massachusetts); Brigham and Women's Hospital (Boston, Massachusetts)

The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)4...

Ages: 10 Years up to 17 Years (ALL) — Inclusion Criteria for Part A and Part B: • 1. Diagnosis of RMS. • 2. EDSS at screening: 0-5.5, inclusive.

TG Therapeutics Investigational Trial Site (Salt Lake City, Utah)

This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod. The study will collect and review ...

Ages: All ages (ALL) — * Adverse event (AE) report with MedDRA Preferred Term of " John Cunningham virus (JCV) cerebrospinal fluid test positive", " JCV granule cell neuronopathy", or "Progressive multifocal leukoencephalopathy (PML)" repor...

Bristol Myers Squibb (Lawrenceville, New Jersey)

People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous res...

Ages: 18 Years up to 65 Years (ALL) — * Confirmed relapsing remitting or secondary progressive MS diagnosis according to the McDonald 2017 criteria • * Expanded Disability Status Scale (EDSS) score \< 7 • * Relapse free period ≥ 3 months

Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo (Buffalo, New York)

There currently is a lack of evidence to support exercise interventions in people with advanced disability due to MS (i.e., need assistance to walk or use a wheelchair). This project proposes to study a strength training program using blood flow restriction...

Ages: 18 Years up to 75 Years (ALL) — 1. Confirmed diagnosis of MS • 3. Patient Determined Disease Steps (PDDS) 4 to 7 • * PDDS 4: Early cane: I use a cane or a single crutch or some other form of support (such as touching a wall or leaning on someone's a...

Rocky Mountain Regional VA Medical Center, Aurora, CO (Aurora, Colorado)

Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that thes...

Ages: 18 Years up to 60 Years (ALL) — * Male or female, 18 to 60 years of age, inclusive. • * Medically stable on the basis of physical examination, medical history, and vital signs • * Must meet McDonald 2024 diagnostic criteria for multiple sclerosis ba...

Johns Hopkins University (Baltimore, Maryland)

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may...

Ages: All ages (ALL) — * Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare/uncommon disease • Exclusion Criteria: • * Diagnosis of a disease which is not rare

Sanford Health (Sioux Falls, South Dakota)

The objective is to understand how amygdala activation affects other medial temporal lobe structures to prioritize long-term memories. The project is relevant to disorders of memory and to disorders involving affect and memory, including traumatic brain inj...

Ages: 18 Years up to 75 Years (ALL) — * Must be able to understand and speak English. • * Able to provide informed consent. • * Diagnosed with epilepsy.

Washington University School of Medicine (St Louis, Missouri)

To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, ran...

Ages: 18 Years (ALL) — 1. \[Patients\] Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease) • 2. \[Patients\] Seen by palliative care inpatient consultation team • 3. \[Patients\] Delirium a...

MD Anderson Cancer Center (Houston, Texas)

Interactions between epilepsy and sleep are numerous and bidirectional. Sleep can facilitate epileptic activity and seizures in several syndromes, while sleep deprivation increases cortical excitability and seizure susceptibility. Conversely, sleep disturba...

Ages: 18 Years up to 55 Years (ALL) — * Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study • * Aged 18 to 55 years old • * Diagnosis of focal temporal or frontal lobe epilepsy ba...

Epilepsy Department, Duke University Hospital (Durham, North Carolina)

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underser...

Ages: 14 Years up to 24 Years (ALL) — * Diagnosed with epilepsy • * Currently prescribed anti-seizure medicine (ASMs) • * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group...

Orlando Health Arnold Palmer Hospital (Orlando, Florida); Orlando Health Orlando Regional Medical Center (Orlando, Florida)

Depression is one of the most common disorders of mental health, affecting 7-8% of the population and causing tremendous disability to afflicted individuals and economic burden to society. In order to optimize existing treatments and develop improved ones, ...

Ages: 21 Years up to 70 Years (ALL) — * Epilepsy cohort: adult patients scheduled to undergo intracranial seizure monitoring who provide informed consent • * Depression cohort: patients enrolled in our DBS for depression trial

Baylor College of Medicine (Houston, Texas)

The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week ...

Ages: 60 Years (ALL) — 1. are African American (self-identify) • 2. are 60 and older • 3. are physically capable of exercise

Pennington Biomedical Research (Baton Rouge, Louisiana)

This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the va...

Ages: 40 Years up to 65 Years (ALL) — * Healthy males and non-pregnant, non-lactating females, 40-65 years old • * BMI between 18.0 and 32.0 kg/m² • * Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI

Palm Springs Community Health Center (Miami Lakes, Florida)

The goal of this clinical study is to investigate the effectiveness of non-invasive stimulation to enhance cognitive control abilities in older adults with and without cognitive impairment. The main questions it aims to answer are: * whether it is possible ...

Ages: 18 Years up to 90 Years (ALL) — * Older adults • 1. Ages between 60 to 90 years • 2. Good general health

Health Discovery Building (Austin, Texas)

Developing efficient cognitive intervention for cognitively health older adults is a major public health goal, due to its potential for reducing age-related cognitive decline and Alzheimer's disease/dementia risk. Executive Control is a relevant cognitive t...

Ages: 60 Years up to 75 Years (ALL) — * Adequate English proficiency • * Willingness to adhere to training protocol: • * Attend 2 in-person assessments

Rutgers New Jersey Medical School, Behavior Health Sciences Building, F-Level (Newark, New Jersey)

The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

Ages: 18 Years (ALL) — Inclusion Criteria: participants must fulfill all of the criteria for one of the following groups. • 1\. Group 1: cognitively and neurologically normal subjects (CN, n=25) • 1. Male or female ≥ 18 years of age current...

Perelman Center for Advance Medicine (Philadelphia, Pennsylvania)

This study aims to recruit patients already implanted with Deep Brain Stimulation (DBS) for movement disorders to complete tasks assessing parameters of motor output, speech, and swallowing functions, both with and without stimulation. DBS parameters would ...

Ages: 18 Years up to 80 Years (ALL) — * Movement disorder patients ≥18 years of age and \< 80 years of age, who will be implanted with DBS for treatment of motor symptoms. • * Subject has provided written informed consent and Health Insurance Portability ...

University of Pittsburgh (Pittsburgh, Pennsylvania)

The primary objective of the proposed pilot study is to assess the safety and tolerability of active patterned Deep Brain Stimulation (pDBS) when administered in a home setting for patients with Parkinson's disease (PD) who have had stable bilateral Subthal...

Ages: 18 Years up to 80 Years (ALL) — * Bilateral STN or GPi DBS with Boston Scientific Vercise Genus DBS System • * Diagnosis of Parkinson's disease as confirmed by a movement disorders fellowship trained neurologist • * Chronic stable DBS therapy, defin...

University of Florida (Gainesville, Florida)

The purpose of this research is to determine if the electrophysiologic data collected from standard-of-care microelectrode recordings during human deep brain stimulation (DBS) surgery will be the same using the MAVEN device compared with the standard Alpha ...

Ages: 18 Years (ALL) — * Mayo Clinic patients already scheduled to undergo DBS surgery with Dr. Kendall Lee fora movement disorder. • Exclusion Criteria: • * Patients not approved for DBS surgery by the multidisciplinary DBS committee.

Mayo Clinic (Rochester, Minnesota)

Development of a central repository for PD-related genomic data for future research.

Ages: 18 Years (ALL) — * Study Population 1: PWP (open for recruitment) • 1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis. • 2. Willingness to undergo genetic testing, and cho...

University of California San Diego (UCSD) (La Jolla, California); University of Southern California (Los Angeles, California); University of California Los Angeles (Los Angeles, California)

Background: A movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Mo...

Ages: 2 Years up to 100 Years (ALL) — * INCLUSION CRITERIA: • In order to be eligible to participate in this study, an individual must meet all of the following criteria: • * Stated willingness to comply with all study procedures and availability for the ...

National Institutes of Health Clinical Center (Bethesda, Maryland)

This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.

Ages: All ages (ALL) — 1. Males and females of diverse racial and ethnic backgrounds, with age across the lifespan; • 2. Patients will have at least one of the forms of dystonia, including focal dystonia (e.g., laryngeal, cervical, oromandi...

Massachusetts Eye and Ear Infirmary (Boston, Massachusetts)

The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.

Ages: All ages (ALL) — * Elevated CK (creatine kinase) • * Evidence of a dystroglycanopathy as determined by review of muscle pathology OR documented mutation in one of the known genes OR abnormal alpha-dystroglycan glycosylation in culture...

University of Iowa, 200 Hawkins Drive (Iowa City, Iowa)

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their caregivers. The question is, What are the effects of communicative interaction on ...

Ages: 18 Years up to 90 Years (ALL) — Speakers with amyotrophic lateral sclerosis (ALS) (PALS-people with ALS) • * diagnosis of ALS following the revised EL Escorial criteria • * no history of other neurological conditions (e.g., stroke)

Speech Core, Pennsylvania State University (University Park, Pennsylvania)

This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected. Blood samples will be used to determine chang...

Ages: 18 Years (ALL) — * Diagnosis of ALS according to Gold Coast Criteria • * Age: 18+ years at enrollment • * Fast-progressing (ALSFRS-R change of at least 1.5 points per month between last 2 measurements at screening)

Duke University Medical Center (Durham, North Carolina)

This study is being done to further develop a device, the mScan, to measure muscle health as compared to measurements of muscle health using MRI (magnetic resonance imaging). This device is held against the skin and uses Electrical Impedance Myography (EIM)...

Ages: 18 Years up to 89 Years (ALL) — * Evidence of a primary myopathic condition as determined by detailed chart review, including results of genetic testing, serological data, or previous muscle biopsy • Exclusion Criteria: • * Inability to lie flat or ...

Beth Israel Deaconess Medical Center (Boston, Massachusetts)

This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.

Ages: 7 Years (MALE) — 1. Must have participated in one of the previous studies with GIVINOSTAT in DMD and have attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and met: • * all the inclusion criteria and n...

University of California - Davis Medical Center - Devis Physical Medicine & Rehabilitation (Sacramento, California); Rady Children's Hospital center - UCSD Department of Neuroscience (San Diego, California)

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

Ages: All ages (ALL) — 1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles. • 2. Willing and able to provide informed consent and to participate in all evaluations. • Exclusion Criteria:

Eden Medical Center (Castro Valley, California); UCSD Moores Cancer Center (La Jolla, California); MemorialCare Health System (Laguna Hills, California)

The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and ...

Ages: 18 Years (ALL) — * At least 18 years old • * Pathologically-confirmed diagnosis of glioblastoma multiforme (GBM) or grade 4 brain tumor • * Participant is accessible for follow-up (has a working email address)

Duke University (Durham, North Carolina)

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the...

Ages: 18 Years up to 85 Years (ALL) — * 18 - 85 years of age • * Cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis • * Able to give informed consent and follow 2-step command.

Medical College of Wisconsin (Milwaukee, Wisconsin)

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment ...

Ages: 18 Years (ALL) — * Adults 18 years or older • * Newly diagnosed glioblastoma (Within 2 months of initial diagnosis by histopathology) • * Not started standard of care chemotherapy and/or radiation therapy for glioblastoma

Cedars-Sinai Medical Center (Los Angeles, California); University of California, San Francisco (San Francisco, California); Pacific Neuroscience Institute / Saint John's Cancer Institute (Santa Monica, California)

This study evaluates a program designed to help individuals transition from inpatient rehabilitation to home following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an e...

Ages: 55 Years (ALL) — * Aged ≥55 years at the time of screening • * Acute stroke diagnosis (IS or ICH) verified by the stroke team or medical record • * Independent in activities of daily living (ADLs) prior to stroke (premorbid Modified R...

University of Missouri (Columbia, Missouri); Washington University in St. Louis (St Louis, Missouri)

This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.

Ages: 14 Years (ALL) — POTS Patients • * Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \< 18) and comply with procedures • * Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ ...

UT Southwestern Medical Center (Dallas, Texas)

The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous ...

Ages: 18 Years (ALL) — * Participants aged 18 years or older. • * Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neu...

Samir Macwan MD Inc (Rancho Mirage, California); Neuro/Psych Sleep Clinic (San Francisco, California)

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-inv...

Ages: 45 Years up to 85 Years (ALL) — * Between the ages of 45 and 85 • * Moderate to severe type II diabetic neuropathy with one or more symptoms including: numbness, tingling, burning, sharp pain, and/or increased sensitivity. • * Diagnosis confirmed by...

Loma Linda University Health Neuropathic Therapy Center (Loma Linda, California)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Ages: 18 Years up to 80 Years (ALL) — Key Inclusion Criteria: • * Body weight greater than or equal to (≥) 45 kilogram (kg) • * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2)

Neuro-Pain Medical Center (Fresno, California); Long Beach Research Institute (Long Beach, California); Angel City Research, Inc (Los Angeles, California)

The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors. The main objective of this st...

Ages: 8 Years up to 12 Years (ALL) — Child Participant Inclusion Criteria: • * Males, females, or non-binary youth between 8 and 12 years of age • * Confirmed diagnosis of Autism Spectrum Disorder (ASD)

Children's Mercy (Kansas City, Missouri)

The Rett Global Registry is a fully remote, global, caregiver-reported registry to collect information about caring for a loved one with Rett syndrome. In addition, caregivers have the ability to track and graph their loved one's symptoms and care strategie...

Ages: All ages (ALL) — 1. Parent/caregiver must be willing and able to provide written informed consent electronically prior to entering data into the registry. • 2. Rett individuals of any age, living or deceased, must have a diagnosis of ...

Rett Syndrome Research Trust (Trumbull, Connecticut)

The purpose of this study is to examine the effect of zolpidem on sleep in children and adolescents with Autism Spectrum Disorder (ASD). Zolpidem is a nonbenzodiazepine GABAa receptor agonist drug that acts as a hypnotic. To accomplish this, the investigato...

Ages: 8 Years up to 17 Years (ALL) — Participants will meet the following • * Outpatients between 8 and 17 years of age with only 12- 17 years of age at time of consent during year 1 • * Diagnostic and Statistical Manual, 5th edition (DSM-5) criteria for...

Stanford University (Stanford, California)

The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are: Will a marijuana-based drug help anxiety in autistic adults? Anxiety c...

Ages: 18 Years up to 45 Years (ALL) — 1. Male or female age 18 to 45 years old with an autism diagnosis. • 2. Participant is ≥ 100 lbs. • 3. Participant or a legally authorized representative provides informed consent/assent for participation in the trial.

Southwest Autism Research and Resource Center (Phoenix, Arizona)

The purpose of this study is to compare CBT VR exposure + VR social skills treatment to CBT Imaginal exposure + mindfulness, in reducing the severity of social anxiety in adults with autism and social anxiety (SA), to identify characteristics associated wit...

Ages: 18 Years (ALL) — * Autism Spectrum Disorder (ASD) (diagnosed by a qualified professional) • * verbal and literate in English or Spanish • * average or greater intellectual ability, based on history and interview

The University of Texas Health Science Center at Houston (Houston, Texas)

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined u...

Ages: 10 Years up to 15 Years (ALL) — * To be eligible to participate in this registry, an individual must meet all the following criteria: • 1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare prov...

CorEvitas, LLC (Waltham, Massachusetts)

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are used to stop the body's "aller...

Ages: 18 Years (ALL) — 1. 18 years of age or older (or the minimum legal adult age as defined per local regulations, whichever is greater) at screening. • Disease Characteristics: • 2. Participants must meet the following Chronic Spontaneou...

Kern Research, Inc. (Bakersfield, California); First OC Dermatology Research Inc (Fountain Valley, California); Antelope Valley Clinical Trials (Lancaster, California)

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigne...

Ages: 6 Years up to 11 Years (ALL) — Inclusion Criteria Children aged 6 to \<12 years at the time of informed consent/assent. • • No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section...

Investigational Drug Service - Rady Childrens Hospital-San Diego (San Diego, California); University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm (San Diego, California)

The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters...

Ages: 18 Years (ALL) — * To be eligible to participate in this registry, an individual must meet all of the following criteria: • 1. Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time...

CorEvitas, LLC (Waltham, Massachusetts)

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will co...

Ages: 12 Years up to 89 Years (ALL) — Participants may be eligible if they: • * Are 12 to 89 years old. • * Have been diagnosed with atopic dermatitis (eczema).

James Y. Wang MD, Inc (Los Angeles, California)

This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the f...

Ages: 10 Years up to 55 Years (ALL) — Food allergy-only group Inclusion Criteria: • * Have a known history of food anaphylaxis to peanut, tree nut, egg, milk, or sesame confirmed by an allergist. • * Have had skin and blood food allergy testing to the foo...

University of Michigan (Ann Arbor, Michigan)

The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit...

Ages: 18 Years (ALL) — 1. Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study. • 2. Age ≥ 18 years at the time of signing the ICF (informed consent). • 3. Diagnosis of hidradenitis suppurativa (...

Virginia Clinical Research, Inc. (Norfolk, Virginia)

A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures inc...

Ages: 18 Years up to 70 Years (ALL) — 1. Male or female subjects between 18 to 70 years of age. • 2. Dermatologic condition that can be addressed by the laser, including but not limited to: • 3. Acne Scars

AVAVA, Inc. (Waltham, Massachusetts)

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

Ages: 18 Years (ALL) — * Male or Female at least 18 years of age, and provide informed consent prior to study procedures. • * Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional t...

University of Alabama at Birmingham (Birmingham, Alabama)

The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions...

Ages: All ages (FEMALE) — Risankizumab-Exposed Cohort • * US resident. • * Current pregnancy.

Evidera, a PPD Business Unit /ID# 238688 (Morrisville, North Carolina); PPD Development, LP /ID# 232134 (Wilmington, North Carolina)

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Ages: 12 Years up to 17 Years (ALL) — * Aged ≥ 12 to \< 18 years at the time of informed consent/assent signing. • * Body weight ≥ 30 kg at both screening and baseline visits. • * Diagnosis of moderate to severe HS for at least 3 months prior to the scree...

University of Alabama At Birmingham (Birmingham, Alabama); Medical Dermatology Specialists Phoenix (Phoenix, Arizona); Saguaro Dermatology (Phoenix, Arizona)

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Ages: 12 Years up to 17 Years (ALL) — * Participants must have stable plaque psoriasis for 6 months or more prior to Screening. • * Participants must have moderate to severe psoriasis defined by:. • i) Psoriasis Area and Severity Index (PASI) ≥ 12, at scr...

Local Institution - 0025 (Fountain Valley, California); Center For Dermatology Clinical Research, Inc. (Fremont, California); Dermatology Research Associates (Los Angeles, California)

Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the Uni...

Ages: 18 Years up to 75 Years (ALL) — * Patients 18 to 75 years of age with moderate to severe alopecia areata (SALT score \>30%). • * Patients with a diagnosis of patch type alopecia areata, totalis, or universalis.. • * Duration of hair loss \>=3 months..

University of Minnesota (Minneapolis, Minnesota)

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Ages: 2 Years up to 18 Years (ALL) — 1. Male or female subjects aged 2 years but less than 18 years • 2. Pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by l...

Derm Texas (Dallas, Texas)

The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is: * Do patient preserve their hair using...

Ages: 18 Years (ALL) — 1. Adults ≥ age 18 with breast cancer stage 1, 2 or 3, who have been deemed appropriate for (neo-)adjuvant chemotherapy and have not yet begun any systemic therapy. • 2. Planned intravenous chemotherapy in the adjuvan...

Inspira Health - Mullica Hills (Mullica Hill, New Jersey); Inspire Health - Vineland (Vineland, New Jersey); Guthrie - Our Lady of Lourdes Memorial Hospital (Binghamton, New York)

This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyan...

Ages: 18 Years (ALL) — General Inclusion Criteria (applicable to subjects in all 4 studied indications) • 1. Males or female subjects, ≥ 18 years of age at the time of signing informed consent. • 2. Ability to understand the requirements of...

IRIS Research and Development, LLC (Plantation, Florida)

An open-label study to evaluate the safety and efficacy of KB111 in pediatric and adult subjects with Hailey-Hailey Disease

Ages: 12 Years (ALL) — * The participant must have read, understood, and signed an Institutional Review Board (IRB)- approved Informed Consent Form and must be willing and able to comply with study procedures and instructions • * Aged ≥ 12 ...

Pediatric Skin Research (Miami, Florida)

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the...

Ages: 18 Years up to 75 Years (ALL) — * Eligible participants must have the following at both screening and baseline: • * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months • * Body surface area (BSA) involvement of 4% to 60%, incl...

Center For Dermatology Clinical Research, Inc. (Fremont, California); Northridge Clinical Trials (Northridge, California); Cura Clinical Research - Oxnard (Oxnard, California)

When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of ...

Ages: 18 Years (ALL) — 1. Must be willing and able to provide written informed consent for the study. • 2. Must have histologically confirmed melanoma for which a Sentinel Lymph Node Biopsy (SLNB) is indicated per the treating physician. • ...

UPMC Hillman Cancer Center (Pittsburgh, Pennsylvania)

Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's resp...

Ages: 18 Years (ALL) — * Age of 18 years or older and able to understand and sign the informed consent form. • * Histologically confirmed diagnosis of unresectable stage III or stage IV melanoma. • * Candidate for standard of care therapy w...

Rutgers Cancer Institute of New Jersey (New Brunswick, New Jersey)

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Ages: 18 Years (ALL) — * Age ≥18 years. • * ECOG performance status of 0 or 1. • * Histologically confirmed:

City of Hope Medical Center (Duarte, California); University of California San Diego Medical Center, Moores Cancer Center (La Jolla, California)

The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.

Ages: 3 Years up to 7 Years (ALL) — Parent inclusion criteria: • i. Adults who currently have children ages 3 and older years of age playing on participating sports teams in leagues serving rural areas in Utah or West Virginia (rural is defined as ≥4 by...

University of Utah (Salt Lake City, Utah); West Virginia University (Morgantown, West Virginia)

Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person. Researchers think adding the drug pembrolizumab...

Ages: 18 Years up to 72 Years (ALL) — -INCLUSION CRITERIA: • 1. Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation. • 2. Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of NCI.

National Institutes of Health Clinical Center (Bethesda, Maryland)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);...

Ages: 18 Years (ALL) — Participants must meet all of the following criteria to be included in the study: • Common Inclusion Criteria for All Participants • 1. Participants must consent to provide a pretreatment tumor sample which has not be...

Valkyrie Clinical Trials (Los Angeles, California); Los Angeles Cancer Network (Los Angeles, California); Pih Health Hematology Medical Oncology (Whittier, California)

The goal of this study is to evaluate the effectiveness of CHAMPION ("Comparative-effectiveness of a Healthy lifestyle and Asthma Management Program, In-person vs ONline"), a primary care-based intervention to address childhood obesity and asthma, and test ...

Ages: 4 Years up to 17 Years (ALL) — Caregiver-proxies will be 18 years old or older, English or Spanish speaking, and a primary caregiver of a child meeting the following criteria: • * Age 4-17.9 years at time of screening • * BMI ≥ 85th percentile

Massachusetts General Hospital (Boston, Massachusetts)

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychia...

Ages: 18 Years up to 75 Years (ALL) — * Moderate to severe persistent asthma • * Treatment with medium to high dose ICS and LABA therapy • * Three or more severe asthma exacerbations (requiring ≥ 3 days of systemic corticosteroids) in the past year

UT Southwestern, 1440 Empire Central, Ste. LD4.100 (Dallas, Texas)

Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors. But some diseases behave differently in people who are n...

Ages: 18 Years up to 115 Years (ALL) — * INCLUSION CRITERIA: • Any person who meets the criteria for inclusion in the study will be considered and must have the patient's signed informed consent for participation. • Autoimmune Disease Diagnosis:

National Human Genome Research Institute (NHGRI) (Bethesda, Maryland)

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are ...

Ages: 18 Years up to 65 Years (ALL) — 1. Male and females ≥ 18 and ≤ 65 years of age at time of consent. • 2. Weight of ≥ 40 kg. • 3. Medical history and biological evidence of active bowel inflammation documented by:

University of California, Davis (Sacramento, California); University of California, San Francisco (San Francisco, California)

The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease. The main question it aims...

Ages: 18 Years (ALL) — 1. Patients at least 18 years old • 2. Patients with mild to moderate Crohn's disease as defined by CDAI score of 150-450 • Exclusion Criteria:

Weill Cornell Medicine (New York, New York)

The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or ...

Ages: 18 Years up to 75 Years (ALL) — * Subject's written informed consent obtained prior to any study-related procedure. • * Patients aged ≥ 18 and ≤ 75 years • * Confirmed diagnosis of asthma (patients must have a documented history of asthma for at lea...

The University of Alabama at Birmingham (Birmingham, Alabama)